CA2146448A1 - 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions - Google Patents
3-substituted 2-oxindole-1-carboxamide pharmaceutical compositionsInfo
- Publication number
- CA2146448A1 CA2146448A1 CA002146448A CA2146448A CA2146448A1 CA 2146448 A1 CA2146448 A1 CA 2146448A1 CA 002146448 A CA002146448 A CA 002146448A CA 2146448 A CA2146448 A CA 2146448A CA 2146448 A1 CA2146448 A1 CA 2146448A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical preparation
- chloro
- weight
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A pharmaceutical preparation comprising:(A) at least one triglyceride or propylene glycol diester of fractionated coconut oil fatty acids; and (B) at least one compound of formula (1) where R1, R2, and R3 are each independently hydrogen, fluoro, bromo, or chloro, or a pharmaceutically acceptable salt thereof.
Description
2 1 4 6 4 4 ~ PCI`/US93/08063 PHARMACEUTICAL COMPOSITIONS
Background of The Invention This invention relates to pharmaceutical compositions comprising certain 3-substituted 2-oxindole-1-carboxamides and medium chain (C8 to C10) fatty acid triglyceride and propylene glycol diesters. These carboxamides are useful as analgesics for use in mammals such as man and in ameliorating or alleviating pain encountered while recovering from surgery or other trauma or in eliminating the symptoms of chronic diseases such as inflammation and pain associated with rheumatoid arthritis and osteoarthritis, as shown in United States Patents 4,556,672 and 5,047,554. The carboxamides are also useful for treating collagenase mediated disorders and diseases, such as bone resorption disorders, corneal ulceration, periodontal disease, inflammatory diseases, and wounds of the skin and burns in a mammal, as shown in United States Patent 5,008,283.
The carboxamides described in formula I are chemically unstable in water. It is known that the rate of hydrolytic degradation may be reduced by protection of labile drugs e.g. sequestration in the hydrophobic core of micelles or formulation in low water activity, non-aqueous solvent-based vehicles i.e. essential oils. In addition to hydrolytic instability the carboxamides are also prone to oxidative degradation in aqueous e.g.
water, and non-aqueous e.g. oils, vehicles. Oxidative instability can be reduced in saturated oils by inclusion of antioxidants or by formulation in unsaturated oils which protect the drug by being preferentially oxidized themselves. However, the carboxamides described in formula I are not readily stabilized in oils commonly used in pharmaceutical preparations e.g. sesame oil, peanut oil, safflower oil, cottonseed oil.
Summary of The Invention The present invention relates to a pharmaceutical preparation comprising:
(A) at least one triglyceride or propylene glycol diester of fractionated coconut oil fatty acids; and (B) at least one compound of the formula WO 94/07488 PCr/US93/08063 44g \\C/~i R ~3 Rl~ / S
~0 ~ ~NH2 where Rl, R2, and R3 are each independently hydrogen, fluoro, bromo, or chloro, or a pharmaceutically acceptable salt thereof, wherein the weight ratio of (A) to (B) ranges from 5.6 to 999.
The pharmaceutical preparation includes 85 to 99 % by weight of (A) and 0.1 to 15 % by weight of (B).
Preferably, Rl, R2, and R3 are each independently fluoro or chloro.
Preferred compounds of formula I include:
5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-carboxamide;
6-chloro-5-fluoro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-in-dole-carboxamide; and 6-chloro-5-fluoro-2 ,3-dihydro-2-oxo-3-(2-(4-chloro)-thienyl-carbonyl)-indole-carboxamide.
The present invention also includes a method of inhibiting activation of collagenase.
The present invention also includes a method of treating an inflammatory disease.
The present invention also includes a method of eliciting an analgesic response.
Detailed Description of the Invention It has been found that pharmaceutical preparations including the carboxamides 30 of formula I and C8 to C10 saturated fatty acid triglycerides and propylene glycol diesters have superior product viability and shelf life. As the result of utilizing such a formulation, the carboxamides are less susceptible to hydrolysis and oxidation which can deteriorate them and ultimately render them ineffective. Stabilization of the WO 94/07488 ~ 1 4 ~ 4 4 8 PCr/US93/08063 carboxamides in these preparations do not require the addition of an antioxidant or other auxiliary stabilizers.
The triglycerides used in the claimed invention are neutral oils which are composed of esters of medium chain (C8 to CI0) fatty acids, also referred to as 5 fractionated coconut oil. These fatty acids are esterified with either glycerin or propylene glycol and are sold under the name MIGLYOL~ (i.e. MIGLYOL~ 810, MIGLYOL~ 812, and MIGLYOL~ 840). MIGLYOLS are also described as triglycerides of fractionated coconut oil fatty acids or caprylic acid/ capric acid triglycerides.
Fractionated coconut oil is prepared from the fixed oils obtained from the dried solid 10 part of the endosperm of Cocos nucifera L by hydrolysis, fractionation of the liberated fatty acids and re-esterification with glycerol or propylene glycol. It consists of a mixture of short and medium-chain saturated fatty acids, mainly octanoic and decanoic acids. Miglyol~ is the trade name for fractionated coconut oil or caprylic acid/capric acid triglycerides from Dynamit Nobel Ltd., Germany and the U.K. These vehicles have 15 demonstrated stability against oxidation and rancidification as well as outstanding safety and biocompatibility. Furthermore, since only saturated fatty acids are used the oils do not generate peroxides or otherfree radicals which could destabilize the pharmaceutical contained therein. The low water content also minimizes the hydrolysis of the carboxamide. In the preferred composition, a carboxamide of formula I is dispersed 20 in an oil vehicle comprising Miglyol~ 812 and other oil-soluble additives described below under agitation to produce a homogenous suspension of the drug substance in the oil vehicle.
Other additives which can be present in the pharmaceutical preparation can include an anticaking agent such as, for example, propylene glycol, polyethylene glycol, 25 glycerin, sorbitol, benzyl alcohol, lecithin, or aluminum stearate. The amount of anticaking agent can range from approximately 0.05 to 5 % by weight. The pharmaceutical preparation can also contain preservative in an amount ranging from 0.5 to 2.0 % by weight. Such preservatives can include, for example, phenol, benzyl alcohol, parabens, chlorbutanol, and benzyl benzoate. Gelling agents, such as 30 aluminum monostearate can also be included in the pharmaceutical preparation in an amount ranging from o.5 to 3.0 % by volume.
The stability of these pharmaceutical preparations can be evaluated, for example, under accelerated storage conditions after subjecting suspensions of the W O 94/07488 PC~r/ U S93/08063 carboxamides (6 % by weight of the drug substance) packaged in glass vials to high temperatures of up to 70C for up to nine weeks. During the stability challenge the level of intact drug remaining in the preparation, as well as hydrolytic and oxidative decomposition products is quantified by high performance liquid chromatography (HPLC). For assay, the suspension is diluted with methanol/triethylamine 100/1 volume-by-volume to give a final drug concentration of 0.6 to 1.2 mg/mL. This solvent dissolves the suspended drug to produce a solution which can be directly injected on the HPLC column. For chromatography, the mobile phase is methanol/water 90/10 v/v + 1% triethylamine, the column is a reversed phase octadecasilane and the solvent flow rate was 1 mL/minute. Drug detection was by UV absorbance at 246 nm. Such an assay has shown there to be virtually no decomposition of carboxamide in suspension after nine weeks.
When a compound of formula I or salt thereof is used in a human subject, the daily dosage will normally be determined by the prescribing physicians. Moreover, the dosage will vary according to the age, weight and response of the individual patient, as well as the severity of the patient's symptoms and the potency of the particular compound being administered. However, for acute administration to relieve pain, an effective dose in most instances will be 0.01 to 0.25 9 as needed (e.g., one- to four-times-a-day). For chronic administration, in most instances an effective dose will be from 0.01 to 0.5 g per day, and preferably 0.1 to 0.25 g per day in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
Preferably the pharmaceutical compositions of the present invention are parenteral pharmaceutical compositions. The pharmaceutical compositions of this invention may be produced by formulating a compound of formula I (as the active ingredient) in dosage unit form. Some examples of dosage unit forms are sterile suspensions for intramuscular, subcutaneous or intra-articular injection, sterile ophthalmic suspensions for topical application to the eye, capsules for oral administration, rectal suppositories, or topical lotion for application to the skin or scalp.
An example of a suitable pharmaceutical dosage for oral administration are soft gelatin capsules. Orally administered suspensions can be delivered, e.g., upon encapsulation of a suspension of compound I in the oil, i.e. Miglyol 812, in a soft gelatin capsule. A rectal suppository may be formulated by dispersing the carboxamide WO94/07488 2I~ PCr/US93/08063 in a neutral oil along with compatible suppository bases, such as cocoa butter or Whitepsol W35, which have melting points above body temperature. A topical product for application to the skin would contain the carboxamide as the active agent dispersed in the neutral oil, e.g., Miglyol 812, and also containing one or more pharmaceutical 5 inactive ingredients, such as: cetyl alcohol, stearic acid, propylene glycol, aluminum monostearate, benzyl alcohol, as diluents and preservatives. A parenteral composition is preferably a suspension of the carboxamide in the neutral oil, and may also contain other inactive pharmaceutical components, such as: benzyl alcohol as preservative, aluminum monostearate as a gelling agent and propylene glycol as a dispersing agent.
The following Example illustrates how the pharmaceutical preparations can be prepared. Commercial reagents can be utilized without further purification.
800 mL of Miglyol 812 was heated to 45C in a compounding vessel equipped 15 with an agitator and homogenizer. 10 g of benzyl alcohol was added to the oil under agitation (about 60-80 R.P.M.). The oil solution was sterile filtered into a sterile compounding vessel equipped wait an agitator and homogenizer. 120 g of micronized, sterile carboxamide powder was dispersed into the oil phase under agitation. Thesuspension was homogenized under high shear for ten minutes and then was allowed20 to cool to room temperature under mild agitation (60-80 R.P.M.). The suspension was brought to a total batch weight of 1000 grams with the addition of the required amount of sterile Miglyol 812 to the suspension to give a final concentration of 12 % by weight of carboxamide in the final formulation. The suspension was aseptically filled into 50 cc, Type 1, flint glass vials using an automated filling apparatus. The vials were capped 25 with teflon-coated rubber stoppers and crimped with aluminum shells.
E)G~MPLE 2 800 mL of Miglyol 812 was heated to 45C in a compounding vessel equipped with an agitator and homogenizer. 10 g of benzyl alcohol was added to the oil under agitation (-60-80 R.P.M.). The oil solution was sterile filtered into a sterile compounding 30 vessel equipped with an agitator and homogenizer. 20 g of sterile, aluminum monostearate powder was added to the oil solution in divided portions under agitation to gel the oil. The gelled oil was allowed to cool to room temperature and allowed to stand for six hours without agitation. 120 g of micronized, sterile carboxamide powder WO 94/07488 PCI'/US93/08063 2l4~448 was then dispersed into the gelled oil under agitation. The suspension was brought to a total batch weight of 1000 grams with the addition of the required amount of sterile, gelled Miglyol 812 to the suspension to give a final concentration of 12% by weight of carboxamide in the final formulation. The suspension was aseptically filled into 50 cc, 5 Type 1, flint glass vials using an automated filling apparatus. The vials were capped with teflon-coated rubber stoppers and crimped with aluminum shells.
800 mL of Miglyol 812 was heated to 45C in a compounding vessel equipped with an agitator and homogenizer. 10 g of benzyl alcohol was added to the oil under 10 agitation (about 60-80 R.P.M.). 120 g of micronized, sterile carboxamide powder was dispersed into the oil phase under agitation. The suspension was homogenized under high shear for ten minutes and then was allowed to cool to room temperature under mild agitation (60-80 R.P.M.). The suspension was brought to a total batch weight of 1000 grams with the addition of the required amount of Miglyol 812 to the suspension 15 to give final concentration of 12% by weight carboxamide in the final formulation. The suspension was filled into soft gelatin capsules using an automated filling apparatus for oral ingestion.
200 g of Miglyol 812 and 800 g of Whitepsol W35 were heated to 60C in a 20 compounding vessel equipped with an agitator and homogenizer. Carboxamide powder was dispersed into the resulting oil solution under agitation. The suspension was allowed to filled into suppository molds and congealed by cooling to room temperature.
Background of The Invention This invention relates to pharmaceutical compositions comprising certain 3-substituted 2-oxindole-1-carboxamides and medium chain (C8 to C10) fatty acid triglyceride and propylene glycol diesters. These carboxamides are useful as analgesics for use in mammals such as man and in ameliorating or alleviating pain encountered while recovering from surgery or other trauma or in eliminating the symptoms of chronic diseases such as inflammation and pain associated with rheumatoid arthritis and osteoarthritis, as shown in United States Patents 4,556,672 and 5,047,554. The carboxamides are also useful for treating collagenase mediated disorders and diseases, such as bone resorption disorders, corneal ulceration, periodontal disease, inflammatory diseases, and wounds of the skin and burns in a mammal, as shown in United States Patent 5,008,283.
The carboxamides described in formula I are chemically unstable in water. It is known that the rate of hydrolytic degradation may be reduced by protection of labile drugs e.g. sequestration in the hydrophobic core of micelles or formulation in low water activity, non-aqueous solvent-based vehicles i.e. essential oils. In addition to hydrolytic instability the carboxamides are also prone to oxidative degradation in aqueous e.g.
water, and non-aqueous e.g. oils, vehicles. Oxidative instability can be reduced in saturated oils by inclusion of antioxidants or by formulation in unsaturated oils which protect the drug by being preferentially oxidized themselves. However, the carboxamides described in formula I are not readily stabilized in oils commonly used in pharmaceutical preparations e.g. sesame oil, peanut oil, safflower oil, cottonseed oil.
Summary of The Invention The present invention relates to a pharmaceutical preparation comprising:
(A) at least one triglyceride or propylene glycol diester of fractionated coconut oil fatty acids; and (B) at least one compound of the formula WO 94/07488 PCr/US93/08063 44g \\C/~i R ~3 Rl~ / S
~0 ~ ~NH2 where Rl, R2, and R3 are each independently hydrogen, fluoro, bromo, or chloro, or a pharmaceutically acceptable salt thereof, wherein the weight ratio of (A) to (B) ranges from 5.6 to 999.
The pharmaceutical preparation includes 85 to 99 % by weight of (A) and 0.1 to 15 % by weight of (B).
Preferably, Rl, R2, and R3 are each independently fluoro or chloro.
Preferred compounds of formula I include:
5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-carboxamide;
6-chloro-5-fluoro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-in-dole-carboxamide; and 6-chloro-5-fluoro-2 ,3-dihydro-2-oxo-3-(2-(4-chloro)-thienyl-carbonyl)-indole-carboxamide.
The present invention also includes a method of inhibiting activation of collagenase.
The present invention also includes a method of treating an inflammatory disease.
The present invention also includes a method of eliciting an analgesic response.
Detailed Description of the Invention It has been found that pharmaceutical preparations including the carboxamides 30 of formula I and C8 to C10 saturated fatty acid triglycerides and propylene glycol diesters have superior product viability and shelf life. As the result of utilizing such a formulation, the carboxamides are less susceptible to hydrolysis and oxidation which can deteriorate them and ultimately render them ineffective. Stabilization of the WO 94/07488 ~ 1 4 ~ 4 4 8 PCr/US93/08063 carboxamides in these preparations do not require the addition of an antioxidant or other auxiliary stabilizers.
The triglycerides used in the claimed invention are neutral oils which are composed of esters of medium chain (C8 to CI0) fatty acids, also referred to as 5 fractionated coconut oil. These fatty acids are esterified with either glycerin or propylene glycol and are sold under the name MIGLYOL~ (i.e. MIGLYOL~ 810, MIGLYOL~ 812, and MIGLYOL~ 840). MIGLYOLS are also described as triglycerides of fractionated coconut oil fatty acids or caprylic acid/ capric acid triglycerides.
Fractionated coconut oil is prepared from the fixed oils obtained from the dried solid 10 part of the endosperm of Cocos nucifera L by hydrolysis, fractionation of the liberated fatty acids and re-esterification with glycerol or propylene glycol. It consists of a mixture of short and medium-chain saturated fatty acids, mainly octanoic and decanoic acids. Miglyol~ is the trade name for fractionated coconut oil or caprylic acid/capric acid triglycerides from Dynamit Nobel Ltd., Germany and the U.K. These vehicles have 15 demonstrated stability against oxidation and rancidification as well as outstanding safety and biocompatibility. Furthermore, since only saturated fatty acids are used the oils do not generate peroxides or otherfree radicals which could destabilize the pharmaceutical contained therein. The low water content also minimizes the hydrolysis of the carboxamide. In the preferred composition, a carboxamide of formula I is dispersed 20 in an oil vehicle comprising Miglyol~ 812 and other oil-soluble additives described below under agitation to produce a homogenous suspension of the drug substance in the oil vehicle.
Other additives which can be present in the pharmaceutical preparation can include an anticaking agent such as, for example, propylene glycol, polyethylene glycol, 25 glycerin, sorbitol, benzyl alcohol, lecithin, or aluminum stearate. The amount of anticaking agent can range from approximately 0.05 to 5 % by weight. The pharmaceutical preparation can also contain preservative in an amount ranging from 0.5 to 2.0 % by weight. Such preservatives can include, for example, phenol, benzyl alcohol, parabens, chlorbutanol, and benzyl benzoate. Gelling agents, such as 30 aluminum monostearate can also be included in the pharmaceutical preparation in an amount ranging from o.5 to 3.0 % by volume.
The stability of these pharmaceutical preparations can be evaluated, for example, under accelerated storage conditions after subjecting suspensions of the W O 94/07488 PC~r/ U S93/08063 carboxamides (6 % by weight of the drug substance) packaged in glass vials to high temperatures of up to 70C for up to nine weeks. During the stability challenge the level of intact drug remaining in the preparation, as well as hydrolytic and oxidative decomposition products is quantified by high performance liquid chromatography (HPLC). For assay, the suspension is diluted with methanol/triethylamine 100/1 volume-by-volume to give a final drug concentration of 0.6 to 1.2 mg/mL. This solvent dissolves the suspended drug to produce a solution which can be directly injected on the HPLC column. For chromatography, the mobile phase is methanol/water 90/10 v/v + 1% triethylamine, the column is a reversed phase octadecasilane and the solvent flow rate was 1 mL/minute. Drug detection was by UV absorbance at 246 nm. Such an assay has shown there to be virtually no decomposition of carboxamide in suspension after nine weeks.
When a compound of formula I or salt thereof is used in a human subject, the daily dosage will normally be determined by the prescribing physicians. Moreover, the dosage will vary according to the age, weight and response of the individual patient, as well as the severity of the patient's symptoms and the potency of the particular compound being administered. However, for acute administration to relieve pain, an effective dose in most instances will be 0.01 to 0.25 9 as needed (e.g., one- to four-times-a-day). For chronic administration, in most instances an effective dose will be from 0.01 to 0.5 g per day, and preferably 0.1 to 0.25 g per day in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.
Preferably the pharmaceutical compositions of the present invention are parenteral pharmaceutical compositions. The pharmaceutical compositions of this invention may be produced by formulating a compound of formula I (as the active ingredient) in dosage unit form. Some examples of dosage unit forms are sterile suspensions for intramuscular, subcutaneous or intra-articular injection, sterile ophthalmic suspensions for topical application to the eye, capsules for oral administration, rectal suppositories, or topical lotion for application to the skin or scalp.
An example of a suitable pharmaceutical dosage for oral administration are soft gelatin capsules. Orally administered suspensions can be delivered, e.g., upon encapsulation of a suspension of compound I in the oil, i.e. Miglyol 812, in a soft gelatin capsule. A rectal suppository may be formulated by dispersing the carboxamide WO94/07488 2I~ PCr/US93/08063 in a neutral oil along with compatible suppository bases, such as cocoa butter or Whitepsol W35, which have melting points above body temperature. A topical product for application to the skin would contain the carboxamide as the active agent dispersed in the neutral oil, e.g., Miglyol 812, and also containing one or more pharmaceutical 5 inactive ingredients, such as: cetyl alcohol, stearic acid, propylene glycol, aluminum monostearate, benzyl alcohol, as diluents and preservatives. A parenteral composition is preferably a suspension of the carboxamide in the neutral oil, and may also contain other inactive pharmaceutical components, such as: benzyl alcohol as preservative, aluminum monostearate as a gelling agent and propylene glycol as a dispersing agent.
The following Example illustrates how the pharmaceutical preparations can be prepared. Commercial reagents can be utilized without further purification.
800 mL of Miglyol 812 was heated to 45C in a compounding vessel equipped 15 with an agitator and homogenizer. 10 g of benzyl alcohol was added to the oil under agitation (about 60-80 R.P.M.). The oil solution was sterile filtered into a sterile compounding vessel equipped wait an agitator and homogenizer. 120 g of micronized, sterile carboxamide powder was dispersed into the oil phase under agitation. Thesuspension was homogenized under high shear for ten minutes and then was allowed20 to cool to room temperature under mild agitation (60-80 R.P.M.). The suspension was brought to a total batch weight of 1000 grams with the addition of the required amount of sterile Miglyol 812 to the suspension to give a final concentration of 12 % by weight of carboxamide in the final formulation. The suspension was aseptically filled into 50 cc, Type 1, flint glass vials using an automated filling apparatus. The vials were capped 25 with teflon-coated rubber stoppers and crimped with aluminum shells.
E)G~MPLE 2 800 mL of Miglyol 812 was heated to 45C in a compounding vessel equipped with an agitator and homogenizer. 10 g of benzyl alcohol was added to the oil under agitation (-60-80 R.P.M.). The oil solution was sterile filtered into a sterile compounding 30 vessel equipped with an agitator and homogenizer. 20 g of sterile, aluminum monostearate powder was added to the oil solution in divided portions under agitation to gel the oil. The gelled oil was allowed to cool to room temperature and allowed to stand for six hours without agitation. 120 g of micronized, sterile carboxamide powder WO 94/07488 PCI'/US93/08063 2l4~448 was then dispersed into the gelled oil under agitation. The suspension was brought to a total batch weight of 1000 grams with the addition of the required amount of sterile, gelled Miglyol 812 to the suspension to give a final concentration of 12% by weight of carboxamide in the final formulation. The suspension was aseptically filled into 50 cc, 5 Type 1, flint glass vials using an automated filling apparatus. The vials were capped with teflon-coated rubber stoppers and crimped with aluminum shells.
800 mL of Miglyol 812 was heated to 45C in a compounding vessel equipped with an agitator and homogenizer. 10 g of benzyl alcohol was added to the oil under 10 agitation (about 60-80 R.P.M.). 120 g of micronized, sterile carboxamide powder was dispersed into the oil phase under agitation. The suspension was homogenized under high shear for ten minutes and then was allowed to cool to room temperature under mild agitation (60-80 R.P.M.). The suspension was brought to a total batch weight of 1000 grams with the addition of the required amount of Miglyol 812 to the suspension 15 to give final concentration of 12% by weight carboxamide in the final formulation. The suspension was filled into soft gelatin capsules using an automated filling apparatus for oral ingestion.
200 g of Miglyol 812 and 800 g of Whitepsol W35 were heated to 60C in a 20 compounding vessel equipped with an agitator and homogenizer. Carboxamide powder was dispersed into the resulting oil solution under agitation. The suspension was allowed to filled into suppository molds and congealed by cooling to room temperature.
Claims (20)
1. A pharmaceutical preparation comprising:
(A) at least one triglyceride or propylene glycol diester of fractionated coconut oil fatty acids; and (B) at least one compound of the formula where R1, R2, and R3 are each independently hydrogen, fluoro, bromo, or chloro, or a pharmaceutically acceptable salt thereof, wherein the ratio of % by weight of (A) to % by weight of (B) ranges from 5.6 to999.
(A) at least one triglyceride or propylene glycol diester of fractionated coconut oil fatty acids; and (B) at least one compound of the formula where R1, R2, and R3 are each independently hydrogen, fluoro, bromo, or chloro, or a pharmaceutically acceptable salt thereof, wherein the ratio of % by weight of (A) to % by weight of (B) ranges from 5.6 to999.
2. The pharmaceutical preparation of claim 1, wherein the preparation includes 85 to 99 % by weight of (A) and 0.1 to 15 % by weight of (B).
3. The pharmaceutical preparation of claim 1, wherein R1, R2, and R3 are each independently fluoro or chloro.
4. The pharmaceutical preparation of claim 1, wherein the compound of formula I is selected from the group consisting of 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-carboxamide;
6-chloro-5-fluoro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-carbox-amide; and 6-chloro-5-fluoro-2 ,3-dihydro-2-oxo-3-(2-(4-chloro)-thienylcarbonyl)-indole-carboxamide.
6-chloro-5-fluoro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-carbox-amide; and 6-chloro-5-fluoro-2 ,3-dihydro-2-oxo-3-(2-(4-chloro)-thienylcarbonyl)-indole-carboxamide.
5. The pharmaceutical preparation of claim 1, wherein the compound of formula I is 5-chloro-2,3-dihydro-2-oxo-3-(2-thienyl- carbonyl)-indole-carboxamide.
6. The pharmaceutical preparation of claim 1, wherein the compound of formula I is 6-chloro-5-fluoro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-carboxamide.
7. The pharmaceutical preparation of claim 1, wherein the compound of formula I is 6-chloro-5-fluoro-2,3-dihydro-2-oxo-3-(2-(4-chloro)-thienylcarbonyl)-indole-carboxamide.
8. The pharmaceutical preparation of claim 1, wherein said coconut oil fatty acids include C8 to C10 fatty acids.
9. The pharmaceutical preparation of claim 8, wherein said coconut oil fatty acids include caprylic acid, caproic acid, lauric acid, and linoleic acid.
10. The pharmaceutical preparation of claim 1, further including 0.05 to 5 % by weight of an anticaking agent .
11. The pharmaceutical preparation of claim 10, wherein said anticaking agent is propylene glycol, polyethylene glycol, glycerin, sorbitol, benzyl alcohol, lecithin, or aluminum stearate.
12. The pharmaceutical preparation of claim 10, further including 0.5 to 2.0 %
by weight of a preservative.
by weight of a preservative.
13. The pharmaceutical preparation of claim 12, wherein said preservative is phenol, benzyl alcohol, parabens, chlorbutanol, or benzyl benzoate.
14. The pharmaceutical preparation of claim 1, wherein said pharmaceutical preparation is adapted to be orally, topically, ophthalmically, parentally, or rectally administered.
15. The pharmaceutical preparation of claim 1, wherein the pharmaceutical preparation includes from 0.01 to 1.0 g of a compound of formula I.
16. The pharmaceutical preparation of claim 15, wherein the pharmaceutical composition includes from 20 to 250 mg of a compound of formula I.
17. A method of inhibiting activation of collagenase in a mammal in need thereof which comprises administering to said mammal a collagenase activation inhibiting amount of the pharmaceutical preparation of claim 1.
18. A method of eliciting an analgesic response in a mammal which comprises administering to said mammal an analgesic response eliciting amount of the pharmaceutical preparation of claim 1.
19. A method of treating an inflammatory disease in a mammal which comprises administering to said mammal an inflammatory disease treating amount of the pharmaceutical preparation of claim 1.
20. A pharmaceutical preparation comprising:
(A) at least one triglyceride or propylene glycol diester of fractionated coconut oil fatty acids;
(B) at least one compound of the formula where R1, R2, and R3 are each independently hydrogen, fluoro, bromo, or chloro, or a pharmaceutically acceptable salt thereof;
(C) 0 to 5 % by weight of an anticaking agent; and (D) 0 to 2.0 % by weight of a preservative, wherein the ratio of % by weight of (A) to % by weight of (B) ranges from 5.6 to999.
(A) at least one triglyceride or propylene glycol diester of fractionated coconut oil fatty acids;
(B) at least one compound of the formula where R1, R2, and R3 are each independently hydrogen, fluoro, bromo, or chloro, or a pharmaceutically acceptable salt thereof;
(C) 0 to 5 % by weight of an anticaking agent; and (D) 0 to 2.0 % by weight of a preservative, wherein the ratio of % by weight of (A) to % by weight of (B) ranges from 5.6 to999.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95793092A | 1992-10-07 | 1992-10-07 | |
| US957,930 | 1992-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2146448A1 true CA2146448A1 (en) | 1994-04-14 |
Family
ID=25500362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002146448A Abandoned CA2146448A1 (en) | 1992-10-07 | 1993-09-02 | 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0662831A1 (en) |
| JP (1) | JP2721042B2 (en) |
| KR (1) | KR950703338A (en) |
| CN (1) | CN1089138A (en) |
| AU (1) | AU676200B2 (en) |
| BR (1) | BR9307182A (en) |
| CA (1) | CA2146448A1 (en) |
| CZ (1) | CZ282702B6 (en) |
| EG (1) | EG20289A (en) |
| FI (1) | FI934387A (en) |
| HU (1) | HUT68533A (en) |
| IL (1) | IL107122A (en) |
| MX (1) | MX9306222A (en) |
| MY (1) | MY109680A (en) |
| NO (1) | NO951350L (en) |
| NZ (1) | NZ256164A (en) |
| PL (1) | PL174170B1 (en) |
| RU (1) | RU2119353C1 (en) |
| TW (1) | TW438798B (en) |
| WO (1) | WO1994007488A1 (en) |
| ZA (1) | ZA937405B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2076106B1 (en) * | 1993-08-26 | 1996-06-16 | Pfizer | PHARMACEUTICAL COMPOSITIONS BASED ON 2-OXINDOL-1-CARBOXAMIDES 3-SUBSTITUTED |
| AU2517095A (en) * | 1994-05-19 | 1995-12-18 | R.P. Scherer International Corporation | Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions |
| SK51296A3 (en) * | 1995-04-24 | 1997-04-09 | Pfizer | Inhibiting photodecomposition of 3-substituted-2-oxindol-1- -carboxamides, a tablet and a capsule |
| WO1998029136A1 (en) * | 1996-12-27 | 1998-07-09 | Takeda Chemical Industries, Ltd. | Stabilized tricyclic compound |
| JP5869764B2 (en) * | 2011-01-07 | 2016-02-24 | 中日本カプセル 株式会社 | Capsule filling composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4556672A (en) * | 1984-03-19 | 1985-12-03 | Pfizer Inc. | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents |
| US5047554A (en) * | 1989-04-18 | 1991-09-10 | Pfizer Inc. | 3-substituted-2-oxindole derivatives |
| US5008283A (en) * | 1990-03-19 | 1991-04-16 | Pfizer Inc. | Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase |
| EP0620728B1 (en) * | 1992-01-13 | 1997-01-08 | Pfizer Inc. | Preparation of tablets of increased strength |
-
1993
- 1993-08-17 TW TW082106612A patent/TW438798B/en active
- 1993-09-02 BR BR9307182A patent/BR9307182A/en not_active Application Discontinuation
- 1993-09-02 AU AU48392/93A patent/AU676200B2/en not_active Ceased
- 1993-09-02 EP EP93921210A patent/EP0662831A1/en not_active Withdrawn
- 1993-09-02 RU RU95111378A patent/RU2119353C1/en active
- 1993-09-02 JP JP6509043A patent/JP2721042B2/en not_active Expired - Lifetime
- 1993-09-02 KR KR1019950701320A patent/KR950703338A/en not_active Application Discontinuation
- 1993-09-02 CA CA002146448A patent/CA2146448A1/en not_active Abandoned
- 1993-09-02 PL PL93308307A patent/PL174170B1/en unknown
- 1993-09-02 CZ CZ95878A patent/CZ282702B6/en unknown
- 1993-09-02 NZ NZ256164A patent/NZ256164A/en unknown
- 1993-09-02 WO PCT/US1993/008063 patent/WO1994007488A1/en not_active Application Discontinuation
- 1993-09-27 IL IL10712293A patent/IL107122A/en not_active IP Right Cessation
- 1993-10-04 EG EG64393A patent/EG20289A/en active
- 1993-10-05 MY MYPI93002026A patent/MY109680A/en unknown
- 1993-10-06 FI FI934387A patent/FI934387A/en not_active Application Discontinuation
- 1993-10-06 ZA ZA937405A patent/ZA937405B/en unknown
- 1993-10-06 CN CN93118904A patent/CN1089138A/en active Pending
- 1993-10-06 MX MX9306222A patent/MX9306222A/en unknown
- 1993-10-06 HU HU9302821A patent/HUT68533A/en unknown
-
1995
- 1995-04-06 NO NO951350A patent/NO951350L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0662831A1 (en) | 1995-07-19 |
| IL107122A (en) | 1998-08-16 |
| ZA937405B (en) | 1995-04-06 |
| HU9302821D0 (en) | 1993-12-28 |
| AU676200B2 (en) | 1997-03-06 |
| PL308307A1 (en) | 1995-07-24 |
| FI934387A0 (en) | 1993-10-06 |
| MX9306222A (en) | 1994-04-29 |
| BR9307182A (en) | 1999-03-30 |
| JP2721042B2 (en) | 1998-03-04 |
| RU2119353C1 (en) | 1998-09-27 |
| NO951350L (en) | 1995-06-06 |
| TW438798B (en) | 2001-06-07 |
| AU4839293A (en) | 1994-04-26 |
| CN1089138A (en) | 1994-07-13 |
| NO951350D0 (en) | 1995-04-06 |
| WO1994007488A1 (en) | 1994-04-14 |
| FI934387A (en) | 1994-04-08 |
| IL107122A0 (en) | 1993-12-28 |
| CZ87895A3 (en) | 1995-10-18 |
| EG20289A (en) | 1998-07-30 |
| JPH07507809A (en) | 1995-08-31 |
| PL174170B1 (en) | 1998-06-30 |
| MY109680A (en) | 1997-04-30 |
| CZ282702B6 (en) | 1997-09-17 |
| HUT68533A (en) | 1995-04-27 |
| NZ256164A (en) | 1997-03-24 |
| KR950703338A (en) | 1995-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0948332B1 (en) | Antiherpetic medicated stick containing acyclovir for topical application | |
| US4938960A (en) | Agents for the treatment and protection of the skin | |
| RU2128505C1 (en) | Lipid-containing pharmaceutical composition | |
| EP1007020B1 (en) | 9-cis-RETINOIC ACID FOR CELL-MEDIATED IMMUNE DISEASES | |
| KR19990067603A (en) | Aqueous suspension of 9-hydroxyrisperidone fatty acid ester | |
| ITMI950529A1 (en) | PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR THEIR PREPARATION | |
| JP4209467B2 (en) | Formulation composition for oral administration | |
| US4612194A (en) | Anti-rheumatic agents and their use | |
| US5795902A (en) | 3-substituted 2-oxindole-1 carboxamide pharmaceutical compositions | |
| CA2146448A1 (en) | 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions | |
| EP0388125A1 (en) | Medicament | |
| KR100475388B1 (en) | Oral gel capsule formulation of 1,2,4-benzotriazine oxides | |
| BG103917A (en) | Sertraline-containing gelatine batched forms | |
| US9731021B2 (en) | Hydrogel composition for the treatment of dermatological disorders | |
| US5494936A (en) | Delivery formulation for probucol | |
| JPH044300B2 (en) | ||
| JPS631923B2 (en) | ||
| JPH0368009B2 (en) | ||
| JPH072676A (en) | Pharmaceutical preparation and/or cosmetic preparation | |
| JPH0390022A (en) | External preparation for treating skin disease | |
| WO1993021909A1 (en) | Improved delivery formulation for lipophilic drugs | |
| EP0339176A1 (en) | Suppository containing a non-steroidal anti-inflammatory medicament | |
| WO2002009670A1 (en) | Liquid or semi-solid pharmaceutical excipient and pharmaceutical composition comprising the same | |
| JPH07267875A (en) | Liquid preparation containing high concentration of aureobasidin | |
| RU92014370A (en) | DRUG FOR TREATMENT OF SEVERE SKIN DISEASES BASED ON 13-CIS-RETINOIC ACID |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |